Ocugen’s Convertible Cash and Reverse Split Vote Set the Table for a Triple-Data Summer

For a clinical-stage biotech, the line between survival and breakout is often drawn by two forces: cash and catalysts. Ocugen finds itself juggling both as it heads into a pivotal shareholder vote on June 11. That meeting will decide whether the company can shrink its share count by as much as eight-to-one, but the real story lies in the gene therapy pipeline that is about to hit its busiest stretch in years.

Shareholders who owned the stock at the close on April 20 are the only ones eligible to vote. The board is asking for approval to implement a reverse stock split at a ratio between 1:2 and 1:8, with discretion over the exact number and timing. Other items on the virtual meeting’s agenda include the election of two Class III directors, the ratification of PwC as auditor, and an advisory vote on executive compensation. The stock ended Tuesday at €1.26 in Frankfurt, down 18.76% over the past month but still up a striking 102.65% over the past twelve months.

A $115 Million Bet on a Longer Runway

The capital structure vote is just one piece of Ocugen’s financial recalibration. In April the company placed convertible notes totaling $115 million with a 6.75% coupon and a 2034 maturity. After closing, Ocugen expects to hold around $112.1 million in cash, enough to fund operations into 2028. There is also an upside kicker: if outstanding warrants held by Janus Henderson are exercised, the company could net an additional $15 million.

The cost of that capital is visible in the conversion terms. The initial conversion price was set at roughly $2.68 per share, representing a 45% premium over the last reported U.S. closing price before the deal was announced. The proceeds are earmarked for general corporate purposes — a broad mandate that will likely cover manufacturing, regulatory filings, and the late-stage trials now ramping up.

Should investors sell immediately? Or is it worth buying Ocugen?

Mixed Quarterly Scorecard

Just ahead of the vote, Ocugen delivered first-quarter results that drew a split verdict. The net loss per share came in at $0.06, a penny worse than the $0.05 the Street had expected. Revenue of $1.53 million, however, easily beat the consensus estimate, even though the absolute figure remains modest.

Operating expenses for the quarter totaled $19.4 million, up from $16.0 million a year earlier. Research and development consumed $11.3 million of that, while general and administrative costs accounted for $8.1 million. Analysts watching the burn rate noted that the cash position at the end of March stood at just $32.2 million — a number that underscores the urgency of the convertible note.

Analysts Hold the Line

Despite the mixed numbers, sell-side coverage remains notably upbeat. Canaccord Genuity stuck with a $12 price target, pointing to the strength of the gene therapy data. Analyst Whitney Ijem highlighted the three lead candidates — OCU400, OCU410ST, and OCU410 — and said that a topline readout from OCU410ST in the third quarter could de-risk the pipeline substantially.

H.C. Wainwright, Chardan Capital, and Oppenheimer also maintained positive ratings, though some of those calls were initiated back in March before the quarterly report. The average analyst price target now stands at $12.33, with a range extending from $8 to $22. The wide spread reflects the binary nature of biotech investing: high upside if the data hits, but little room for error.

Three Programs, Three Milestones

The lab work is where the narrative truly pivots. Ocugen is pursuing three distinct gene therapies, each with a near-term catalyst.

For OCU400, a treatment for retinitis pigmentosa, the company plans to submit a rolling Biologics License Application starting in the third quarter of 2026, with completion expected in the second quarter of 2027. A potential FDA approval is targeted for the fourth quarter of 2027. The pivotal liMeliGhT study has already finished enrollment with 140 patients. Manufacturing validation is slated to advance in the second quarter.

OCU410, aimed at geographic atrophy secondary to age-related macular degeneration, showed encouraging early data: after one year, lesion growth was reduced by 31% with the mid-dose compared to the control arm. The registrational Phase 3 trial is set to begin in the third quarter, with a design that calls for up to 300 participants and a statistical power exceeding 95%. Ocugen hopes to file for approval by 2028.

Ocugen at a turning point? This analysis reveals what investors need to know now.

The third candidate, OCU410ST for Stargardt disease, has already enrolled 63 patients in under nine months. An interim analysis covering 24 patients after eight months is planned for the third quarter, with topline data expected next year. The speed of recruitment suggests strong investigator interest in a disease with few approved options.

Commercially, Ocugen has taken an early step by granting exclusive rights to OCU400 in South Korea to Kwangdong Pharmaceutical. The deal includes upfront payments, near-term milestones, and royalties — a modest but meaningful validation of the asset’s market potential.

June Vote, Summer Data

The June 11 vote will give the board more flexibility to manage the share structure, but it does nothing to change the core investment thesis: Ocugen must now execute on a tight clinical schedule. The third quarter brings simultaneous inflection points for all three programs. If the data come through as analysts hope, the stock’s recent volatility may prove to have been a buying opportunity. If the milestones slip, the convertible debt will serve as a cushion — but the clock will continue ticking.

Ad

Ocugen Stock: New Analysis - 13 May

Fresh Ocugen information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Ocugen analysis...

en | US67577C1053 | OCUGEN’S | boerse | 69323644 |